Woodcock Open To Endpoint Flexibility For Rare Diseases

 
• By Sarah Karlin-Smith
  
zebra
Combinations of multiple endpoints may be possible for rare-disease trials, Woodcock says.

More from Rare Diseases

More from Pink Sheet